What Naitive does

Naitive Technologies Limited is a UK-based medical technology company that has built an AI-driven platform for opportunistic bone health assessment within orthopedic care pathways. The company's flagship product, OsteoSight, is an FDA 510(k)-cleared software medical device that estimates bone mineral density (BMD) from standard hip or pelvic X-rays in patients aged 50 and older, flagging cases at risk for low BMD without requiring additional imaging protocols or changes to existing radiology workflows. This Capture-stage technology is positioned as the foundation of a broader three-stage bone health platform: Convert (referral-to-treatment conversion automation with a stated 20% conversion uplift) and Coordinate (care coordination and insurer letter automation, including AI-drafted denial response letters).

The company's AI capabilities center on a proprietary image processing pipeline that performs metalwork detection, body part segmentation, subregional ROI isolation, and model inference, validated on 29,990+ X-rays at 80% specificity. Beyond the core computer vision model, Naitive applies generative AI for drafting insurer correspondence and process automation across the patient journey. The platform is sold via a sales-led, enterprise field sales motion targeting US orthopedic practices and surgeons, with research collaborations across JIS Orthopedics, Utah Orthopaedics, Sah Orthopaedic Associates, RNOH NHS Trust, and Heraeus Medical serving as clinical validation beachheads and reference sites. Revenue mechanics are undisclosed but characterized as B2B enterprise software with implicit recurring/subscription characteristics; the company has not publicly disclosed pricing or commercial contract terms, and no paying-customer logos are reported.

Naitive is registered in England and Wales (company number 11145951), headquartered in Holborn, London, and operates with 11-50 employees. The company is at an early commercial stage, having only recently received FDA 510(k) clearance in September 2025 following FDA Breakthrough Device Designation in October 2023. Prior capital has been sourced primarily from non-dilutive Innovate UK grants totaling approximately £690k (December 2023) and $437k (August 2024). Leadership is led by founder and CEO Dr. Will Briggs, with a board chaired by Paul Triniman and notable advisory credibility from Prof. Sir Mike Brady, Prof. Tim Briggs CBE, Prof. Jay Parvizi, Prof. Felicia Cosman, Prof. Bob Pignolo, and Prof. Kassim Javaid.

Name

Naitive

Legal name

Naitive Technologies Limited

Website

https://naitive.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Naitive Technologies is a UK-based medical AI company that sells OsteoSight, an FDA 510(k)-cleared software that estimates bone mineral density from routine hip and pelvic X-rays to flag orthopedic patients aged 50+ at risk of low BMD. It targets US orthopedic practices via an enterprise sales-led motion, with research partners including JIS, Utah Orthopaedics, Sah, RNOH, and Heraeus Medical.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

General Orthopedics (HLAKALAA)

Keywords

• AI bone density assessment
• Opportunistic osteoporosis screening
• Orthopedic imaging software
• Medical AI imaging platform
• Bone health SaaS

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. OsteoSight software licensing to orthopedic practices: Following FDA 510(k) clearance in September 2025, Naitive is advancing commercial partnerships to deploy OsteoSight into US orthopedic practices as a proactive bone health management solution, creating new growth opportunities for providers. Specific pricing or licensing terms are not publicly disclosed; appears to be B2B enterprise software with recurring/subscription characteristics.
2. Non-dilutive grant funding: Naitive received a £690k Innovate UK Advancing Precision Medicine programme grant in December 2023 to fund prospective clinical studies with RNOH, indicating active pursuit of public grant funding to support R&D and clinical validation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Naitive sells OsteoSight, an FDA 510(k)-cleared AI medical imaging software that opportunistically estimates bone mineral density (BMD) from standard hip or pelvic X-rays of patients aged 50+ and surfaces at-risk patients to orthopedic surgeons as a notification report. The product is the Capture-stage module of a broader bone health platform that is being extended with referral-to-treatment conversion tools and care-coordination/AI-drafted insurer-letter automation, sold B2B to orthopedic practices on a recurring subscription basis.

Product overview

Naitive offers a single unified AI platform for proactive bone health management in orthopedic care, organized as a pathway-driven architecture with three sequential stages — Capture, Convert, and Coordinate — sitting on top of its FDA 510(k)-cleared flagship product, OsteoSight™. OsteoSight is the Capture-stage AI medical device that opportunistically estimates bone mineral density (BMD) from standard X-rays and flags at-risk patients pre-operatively; the Convert module (Coming Soon) then aims to boost referral-to-treatment conversion rates by 20%; and the Coordinate module closes the loop by automating referral pathway setup, patient tracking, and insurer letter generation (including AI-drafted denial response letters). Together these form a comprehensive bone health platform that helps orthopedic practices identify patients earlier, intervene sooner, and grow services/revenue.

Differentiator

Problem solved

Functional benefit

Brands

• OsteoSight: FDA-cleared, AI-enabled technology that opportunistically estimates bone mineral density (BMD) from routine hip and pelvic X-rays in patients 50 years and older, and Naitive's flagship bone health assessment product.

Products and services

• OsteoSight FDA 510(k)-cleared, AI-enabled medical imaging software that opportunistically estimates bone mineral density (BMD) from standard hip or pelvic X-rays in patients aged 50+ and identifies cases at risk for low BMD, returning a notification report to aid the interpreting physician. Embedded in routine orthopedic imaging workflows without altering existing protocols; serves as the Capture-stage module of Naitive's broader bone health platform and is sold B2B to US orthopedic practices on a recurring subscription basis.

Quantifiable outcome

• 20% boost in referral-to-treatment conversion
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and moderate.

• Heraeus MedicalcoreStrategic or Co-development Partner · 23 October 2025Research collaboration announced October 23, 2025 to characterize bone health and fixation method choices in primary elective THA and TKA patients using Naitive's OsteoSight. Heraeus Medical brings expertise in bone cements and biomaterials for surgical orthopedics (e.g., PALACOS), supporting data-driven analysis of cementless vs cemented fixation among patients with varying bone quality.
• Sah Orthopaedic AssociatescoreStrategic or Co-development Partner · 23 October 2025Clinical research partner in the Heraeus Medical collaboration, contributing real-world clinical data from joint replacement patients in northern California. Sah Orthopaedic Associates performs the most hip and knee replacement surgeries in northern California and provides the clinical component of the THA/TKA bone health characterization study.
• Utah OrthopaedicscoreStrategic or Co-development Partner · 27 August 2025Research partnership announced August 27, 2025 to assess prevalence of low bone mineral density in the local population using OsteoSight on retrospective data, and to evaluate OsteoSight BMD estimates vs DXA (gold standard). Utah Orthopaedics is the only comprehensive single-office orthopedic provider in the Rocky Mountain region and runs an on-site Bone Health Clinic directed by Alexandra Rocco, PA-C.
• JIS Research Institute (JIS Orthopedics)coreStrategic or Co-development Partner · 8 July 2025Research collaboration announced July 8, 2025 to investigate prevalence of low BMD in patients at JIS Orthopedics using OsteoSight and its association with surgical outcomes in primary total hip arthroplasty (THA). Study led by Principal Investigator Dr. David Crawford (Medical Director of JIS Research Institute). JIS Orthopedics has two Ohio clinic locations (New Albany and St. Clairsville) and is a partner practice of OrthoAlliance.
• Pre-Competitive Consortium on Osteoporosis and Bone Health (PRECCO)moderateStrategic or Co-development Partner · 4 April 2024Consortium membership announced April 4, 2024. PRECCO supports the partnership between ESCEO, the International Osteoporosis Foundation (IOF), and the World Health Organization (WHO) on a 5-year strategic roadmap of research and publication deliverables addressing osteoporosis as a global public health challenge. Aligns with Naitive's mission of earlier detection, precise diagnosis, and optimal treatment of chronic bone diseases.
• Royal National Orthopaedic Hospital NHS Trust (RNOH)coreStrategic or Co-development Partner · 15 December 2023Clinical study partner for Innovate UK-funded prospective cross-sectional study assessing accuracy of OsteoSight opportunistic osteoporosis screening in real-world NHS setting. Study led by Prof. Richard Keen (Director, Metabolic Bone Disease Centre) and Dr. Jude Bubbear (Consultant Rheumatologist). Patients have OsteoSight-assessed X-rays compared against DXA gold standard and complete bone health questionnaires.
• Paul Triniman (Chairman of Naitive Board)coreOthersPaul Triniman serves as Chairman of Naitive's Board of Directors, supporting company governance and strategic direction.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ImageBiopsy Lab: ImageBiopsy Lab develops AI-enabled musculoskeletal imaging tools, including AI hip and spine X-ray analysis that overlap directly with Naitive's OsteoSight opportunity to extract BMD insights from routine orthopedic X-rays. Most directly comparable product offering and target user (orthopedic and radiology clinicians).
• Optasia Medical: Optasia Medical builds opportunistic CT-based bone density and spine-fracture assessment AI, competing for the same 'opportunistic screening' workflow that Naitive targets. Competes on the same buyer (radiology/orthopedic practices) and the same clinical problem (missed osteoporosis/fragility fractures).
• Gleamer: Gleamer provides AI bone-fracture detection on X-rays, with deep penetration into European radiology and emergency-medicine workflows. Competes for AI-driven bone-related decision support on routine X-rays, though with a fracture-detection focus rather than BMD assessment.
• AZmed: AZmed offers AI tools for bone-fracture detection on X-rays, with FDA clearance and CE marking across trauma and chest workflows. Comparable regulatory pathway, similar imaging AI modality, and overlapping hospital/orthopedic customer base.

Broad incumbents

• Nanox AI (formerly Zebra Medical Vision): Nanox AI operates a broad AI imaging suite that includes opportunistic bone-health and population-health screening from routine CT scans. Larger and more diversified, but overlapping in the opportunistic-screening value proposition aimed at providers and payers.
• Aidoc: Aidoc sells a comprehensive radiology AI platform covering multiple modalities and clinical findings, with strong US hospital-system penetration. Represents the broader-platform incumbent risk: an Aidoc-style suite could add opportunistic BMD as a feature and undercut standalone point solutions.
• Annalise.ai: Annalise.ai offers a broad, multi-finding chest X-ray and CT AI platform deployed across health systems globally. Comparable in AI-X-ray modality and enterprise B2B healthcare sales motion, though covering many clinical findings rather than specializing in bone health.
• Qure.ai: Qure.ai builds deep-learning radiology AI across head CT, chest X-ray, and musculoskeletal indications, with global regulatory clearances. Comparable imaging AI business model and enterprise healthcare sales motion; covers some overlapping orthopedic/bone use cases.
• icometrix: icometrix develops AI medical imaging SaaS for neurological and musculoskeletal quantification, sold to hospitals and radiology practices under recurring enterprise licenses. Comparable SaaS-to-radiology go-to-market and FDA-cleared AI medical device positioning, though focused on neuro/MSK quantification rather than opportunistic BMD.
• Hologic: Hologic is a major women's-health and bone-densitometry incumbent (Discovery DXA systems and related bone-health franchise). Represents the legacy DXA standard-of-care that Naitive positions OsteoSight against as a more scalable, opportunistic alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/naitive

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naitive